A cell line that maintains favorable growth and productivity characteristics is vital for biopharmaceutical manufacturing processes, whether you are producing monoclonal antibodies, recombinant proteins, or viral vectors for gene therapies. Our ready-to-use cell line systems can accelerate your upstream development by greatly reducing the time, cost, and risk of developing new cell lines. Our cell lines are rationally engineered and designed for compliant biomanufacturing.
Key features include:
Flyer: Sf-RVN® Platform
Product Information Sheet: Sf-RVN® Insect Cell Line
Product Information Sheet: EX-CELL® CD Insect Cell Medium
White Paper: Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium
White Paper: Considerations for Bioreactor Process Development and Scale-up for Transient Transfection-based Lentivirus Production in Suspension
White Paper: A Multifaceted Strategy for Viral Safety in AAV Processes
Brochure: VirusExpress® 293 Production Platform
Data Sheet: VirusExpress® AAV Production Platform
Data Sheet: VirusExpress® Lentivirus Production Platform
The majority of Spodoptera frugiperda cells (such as Sf9) contain a rhabdovirus that is considered a process contaminant and must be eliminated during the bioprocess.
Our Sf-RVN® Platform offers a rhabdovirus-free alternative for bioprocesses and enhances risk mitigation.
The Sf-RVN® Platform is a synergy between a Sf9 rhabdovirus-negative cell line with companion chemically defined medium, specifically formulated to get excellent growth and productivity of the cell line.
Combined, the Sf-RVN® Insect Cell Line with companion EX-CELL® CD Insect Cell Medium provide a high performant platform optimal to produce recombinant proteins, viral vaccines such as viral like particles (VLP) and adeno-associated vectors (AAV) for gene therapy applications.
For more information on the Sf-RVN® Insect Cell Line or to order, please click here.
Our CHOZN® platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes:
Three CHOZN® cell lines are available:
Powered by CompoZr® Zinc Finger Nuclease (ZFN) technology, the well-known and widely adopted CHOZN® GS-/- cell line can help shorten cell line development time lines by up to eight weeks while ensuring excellent stability, with >75% of clones maintaining >70% titer of 60 generations.
Optimized expression vectors for the CHOZN® GS -/- cell line include:
Figure 1.The VirusExpress® Lentivirus Production Platform features a suspension adapted HEK293T cell line, chemically defined medium, and production process with proven performance.
Our VirusExpress® platform offers a transfection-based solution for lentiviral (LV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at clinically relevant scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients. Attributes include:
VirusExpress® 293T Lentiviral Production Cells are optimized for production of lentiviral vectors for gene therapy applications. Comprehensive user protocols guide you from seed train through at-scale transfection and virus production, allowing seamless scale-up. Robust quality documentation enables regulatory filings and commercialization of your gene-modified cell therapy.
Figure 2.The VirusExpress® AAV Production Platform features a suspension adapted HEK293 cell line, chemically defined medium, and production process with proven performance.
The VirusExpress® AAV Production Platform offers a transfection based solution to Adeno-Associated Viral (AAV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to commercial production. VirusExpress® offers the flexibility to use either our contract manufacturing capabilities or your own facilities to speed your therapy to patients.
We have the right cell lines, media products, manufacturing technologies and expertise to meet our customers’ timelines and their patients’ needs. By utilizing the VirusExpress® AAV Production Platform, we estimate you may be able to begin clinical manufacture in as little as 6 months as opposed to ~3 years for a custom cell line and process since clone selection, cell line development and GMP cell banking are complete, as well as substantial process development and largescale bioreactor development. Leveraging our expertise in viral vector manufacturing as well as utilizing our templated process solutions will help deliver your gene therapy to patients faster.